ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[Efficacy and safety of super electroconvulsive therapy for treatment-resistant depression: a retrospective analysis of 292 cases].
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the efficacy and safety of super electroconvulsive therapy (ECT) for treatment-resistant depression (TRD).
methodsThis cohort study was conducted among 292 patients with TRD, who received super ECT from December, 2024 to June, 2025. Eighty-eight of the patients received one electrical stimulation in each super ECT procedure (E1 group), 89 had 2 electrical stimulations (E2 group), and 39 had 3 electrical stimulations (E3 group). The correlation between depression, anxiety and sleep quality at baseline was analyzed. The patients were evaluated using 17-items Hamilton Depression Scale (HAMD-17) at 1, 3, and 6 months after the first super ECT session, and the treatment remission rate and response rate were compared among the 3 groups. The number of sessions and incidences of adverse events within 6 months were compared, and the EEG seizure duration at the first super ECT session was analyzed.
resultsSeventy-four patients (84.09%) in group E1, 76 (76.40%) in group E2, and 32 (82.05%) in group E3 achieved remission within 6 months after super ECT. The average number of treatment sessions was 2.13±1.44 in Group E1, 2.23±2.01 in Group E2, and 2.41±2.15 in Group E3 within 6 months. The baseline HAMA, HAMD-17 and PSQI scores were significantly correlated (
conclusionsSuper ECT is safe and effective for treatment of TRD patients with a total seizure duration longer than 180 s. The number of electrical stimulations in each treatment session does not significantly affect the therapeutic efficacy of super ECT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.